T2 Biosystems meldet Zahlen für Q2/19

• Umsatz 2 Mio. $
  
• Verlust 16 Mio. $
  
• Cash 28 Mio. $
  
• fragwürdige Finanzierung
  

Financing Agreement Highlights:

• The Company entered into two financing agreements that enables the potential access to up to $60 million of additional capital, potentially strengthening its financial position.
  
• Entered into an At-the-Market (ATM) equity offering agreement with Canaccord Genuity LLC pursuant to which Canaccord will, at the Company’s option, use reasonable best efforts to sell up to $30 million of our common stock at our direction.
  
• Entered into common stock purchase and registration rights agreements with Lincoln Park Capital Fund, LLC  (LPC), a Chicago-based institutional investor, under which we will have the right and the sole discretion to sell to LPC up to $30 million worth of shares over a 36-month period at market rates based on closing prices in the past 10 days from when a sales of shares may occur, subject to certain limitations under the agreement as further described below under the section titled "Financing Agreement Details".
  

http://investors.t2biosystems.com/news-releases/...ancial-results-and

T2 erhält Funding von BARDA

"...announced today that it has been awarded a milestone-based contract of initial value of $6 million with a potential value of up to $69 million, if all contract options are exercised, from the Biomedical Advanced Research and Development Authority (BARDA) ..."

http://investors.t2biosystems.com/news-releases/...advance-technology

Zahlen für Q3/19

• Umsatz 1,6 Mio. $
  

"The Company believes that an additional $40 million of capital is required to achieve neutral cash flow."

http://investors.t2biosystems.com/news-releases/...ancial-highlights#

vorläufige Zahlen

• Q4/19 Umsatz ~3 Mio. $
  
• Ende Q4/19 Cash ~ 11 Mio. $
  
• MK 54 Mio. $
  

http://investors.t2biosystems.com/news-releases/...ourth-quarter-2019

Zahlen für 2019

• Umsatz 8,3 Mio. $ (davon 3,1 Mio. $ in Q4)
  
• Verlust 59 Mio. $ (davon 14 Mio. $ in Q4)
  
• Cash 11 Mio. $
  
• negatives Eigenkapital
  
• MK 34 Mio. $
  

"Management projects revenue for the full year 2020 to range from $14.0 million to $17.0 million,including product revenue between $8.0 million and $10.0 million and research and grant contribution revenue of $6.0 million to $7.0 million "

Angesichts des hohen Verlustes und des niedrigen Cashbestands bin ich eher skeptisch was die kurzfristigen Zukunftsaussichten anbetrifft. Siehe auch Posting #70

http://investors.t2biosystems.com/news-releases/...and-full-year-2019